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Impact of Implementation of
the High-Sensitivity Cardiac
Troponin T Assay in a
University Hospital Setting
To the Editor:
The performance of the high-
sensitivity cardiac troponin T as-
say (hs-cTnT)1 has been evalu-
ated in a multicenter study (1 ).
Effective July 2009, we replaced
the fourth-generation troponin T
assay (cTnT) with the hs-cTnT
assay in clinical practice. This
study audits the impact of this
implementation.
The hs-cTnT, implemented
on the cobas e 411 platform (Roche
Diagnostics), fully replaced the
cTnT performed on the Elecsys
2010 analyzer [cutoff, 30 pg/mL—
based on actual assay performance
(10% CV concentration)]. We ob-
tained a detection limit of 5 pg/mL,
a 99th percentile of 15 pg/mL, lim-
ited comparability with the cTnT
at concentrations100 pg/mL (on
average, a 30-pg/mL cTnT concen-
tration yielded a value of approxi-
mately 65 pg/mL with the hs-
cTnT) and mean CVs of 9.1% for
the cTnT (at 39 pg/mL) and 8.5%
for the hs-cTnT (at 17 pg/mL). We
retrieved hs-cTnT results for the
first 3 months after implementa-
tion (July 16 to October 15, 2009)
and cTnT results for the same pe-
riod 1 year previously. Results were
dichotomized as positive or nega-
tive with respect to cutoffs. Among
troponin-positive patients with at
least 2 results during their exam-
ination, we divided marker-
release curves on the basis of typ-
ical or atypical kinetics. We
defined as “typical” an increasing
or decreasing pattern showing a
troponin change between 2 con-
secutive samples exceeding
46% for increasing troponin
results and 32% for decreasing
results. Otherwise, the troponin
pattern was considered “atypical.”
For definition of these percentage
changes, we referred to the short-
term biological variation for tro-
ponin I (2). We are aware, however,
that the 2 cardiac troponins may
have different biological kinetics in
blood, so their biological variation
may be different.
In the evaluated period, 2287
hs-cTnT tests were performed dur-
ing 1371 examinations of 1137 pa-
tients. Correspondingly, 2170
cTnT tests were performed during
1409 examinations of 1205 pa-
tients. After hs-cTnT implementa-
tion, a 5.4% increase in the
hospital-wide test volume was re-
corded, despite a slight decrease in
the number of admitted patients
and examinations. The mean (SD)
number of troponin tests per ex-
amination was 1.54 (1.0) before
and 1.67 (1.1) after hs-cTnT imple-
mentation (P  0.0001), with a
single test ordered in 67.5% and
60.2% of examinations, respec-
tively. The distribution of troponin
orders and positive-test rates in
different wards is shown in Table 1.
A positive result was found in
31.7% of cTnT tests and in 58.7%
of hs-cTnT tests (relative differ-
ence, 85%), corresponding to
25.3% and 51.6% positive exami-
nations, respectively (P 0.0001).
Of all the hs-cTnT positive results,
64% fell in the 16–65 pg/mL inter-
val, previously negative with the
cTnT. In the emergency depart-
ment after hs-cTnT implementa-
tion, the number of hospitalized
patients with positive troponin re-
sults increased from 158 to 292
(85%), but the rate of admission
in intensive care and non–
intensive care departments was
unchanged (P  0.108). In the
same periods, 16 cTnT-positive
patients (8.5%) and 109 hs-
cTnT–positive patients (26.6%)
were discharged. Of these dis-
charged patients, 1 cTnT-positive
patient and 13 hs-cTnT–positive
patients were readmitted to the
emergency department in the
subsequent 2 months (P 0.804,
between the 2 assays).
We audited 458 cTnT and 546
hs-cTnT curves, of which 39.1%
and 69.0%, respectively, had at
least 1 positive result (P 0.0001).
The difference in the percentage of
positive curves displaying a typical
marker release was not significant
(17.2%for the cTnTvs20.5%for the
hs-cTnT, P 0.32). A higher abso-
lute number of typical positive
curves was observed after hs-
cTnT implementation (from 79
to 112). This increased ability to
detect events involving acute
marker release was fully ex-
plained by the number of typi-
cally positive curves in which the
hs-cTnT result never exceeded 65
pg/mL (n  38).
The replacement of the cTnT
with the hs-cTnT markedly in-
creased the rate of positive tests. A
similar outcome was previously
described for a contemporary sen-
sitive troponin I assay (3 ). What is
unique in our experience is the
magnitude of the increase in posi-
tive results after hs-cTnT introduc-
tion, which was based on imple-
1 Nonstandard abbreviations: hs-cTnT, high-
sensitivity cardiac troponin T assay; cTnT, fourth-
generation troponin T assay.
Letters to the Editor
Clinical Chemistry 57:8 (2011) 1211
menting this assay in a routine
protocol. The number of exami-
nations with positive results in-
creased from approximately 25%
to 50%. Although the hs-cTnT
could appear confounding as a
test less specific for the diagnosis
of myocardial infarction (4 ), we
were unable to demonstrate dif-
ferences in the percentage of
curves with a typical marker re-
lease when we compared the
cTnT and the hs-cTnT. An
interpretative approach based
on the demonstration of a
pathophysiology-defined release
of troponin in the blood may al-
low the same specificity perfor-
mance to be achieved when using
different generations of troponin
T assays, thus supporting the use
of serial testing for clinical
decisions (5 ).
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Table 1. Distribution of cardiac troponin orders and positive test rates in different hospital wards.
Orders, n
(% of total)
hs-cTnT/cTnT
difference
Positive tests, n
(% of total ordered tests)
hs-cTnT/cTnT
difference PcTnT hs-cTnT cTnT hs-cTnT
Emergency department 1472 (67.8%) 1465 (64.1%) 0% 272 (18.5%) 664 (45.3%) 145% 0.0001
Internal medicine 184 (8.5%) 293 (12.8%) 59% 121 (65.8%) 263 (89.8%) 117%
Intensive care unit 133 (6.1%) 104 (4.5%) 22% 92 (69.2%) 88 (84.6%) 4%
Cardiology 99 (4.6%) 105 (4.6%) 6% 45 (45.5%) 78 (74.3%) 73%
Pneumology 72 (3.3%) 45 (2.0%) 38% 55 (76.4%) 41 (91.1%) 25%
Surgery 50 (2.3%) 40 (1.7%) 20% 19 (38.0%) 29 (72.5%) 53%
Othersa 44 (2.0%) 64 (2.8%) 45% 13 (29.5%) 33 (51.6%) 200%
Infectious disease 42 (1.9%) 70 (3.1%) 67% 22 (52.4%) 56 (80.0%) 155%
Neurology 27 (1.2%) 19 (0.8%) 30% 15 (55.6%) 19 (100.0%) 27%
Orthopedics 23 (1.1%) 36 (1.6%) 57% 14 (60.9%) 27 (75.0%) 93%
Nephrology 13 (0.6%) 45 (2.0%) 246% 12 (92.3%) 43 (95.6%) 207%
Oncology 11 (0.5%) 1 (0.04%) 91% 7 (63.6%) 1 (100.0%) 86%
All clinical wards 698 (32.2%) 822 (35.9%) 18% 415 (59.5%) 678 (82.5%) 63% 0.0001
Total 2170 (100.0%) 2287 (100.0%) 5.4% 687 (31.7%) 1342 (58.7%) 95% 0.0001
a All wards accounting for 10 tests were gathered into this group.
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